Cell viability was determined in AML cell lines treated with increasing dosages of single compounds and in combination treatments using the STAT5 inhibitor AC-4-130 and a variety of targeted therapies, including the BMI-1 inhibitor PTC596, the MCL1 inhibitor S63845, and the MEK inhibitor trametinib (Figure 3). This evidence concerns the gene MAP2K7 and acute myeloid leukemia.